|
 |
|
|||||||
|
|||||||||
DOI: 10.2337/diacare.29.02.06.dc05-1626
© 2006 by the American Diabetes Association
Pathophysiology/Complications |
Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes
1 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
2 GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania
3 Western General Hospital, Edinburgh, U.K.
Address correspondence and reprint requests to Christopher Ryan, 3501 Forbes Ave., Suite 718, Pittsburgh, PA 15213. E-mail: ryancm{at}upmc.edu
OBJECTIVE—The goals of this study were to determine whether improvements in metabolic control can ameliorate the cognitive dysfunction associated with type 2 diabetes and evaluate the possibility that such improvements are mediated by changes in circulating insulin or insulin resistance.
RESEARCH DESIGN AND METHODS—This randomized double-blind trial enrolled 145 subjects at 18 centers in the U.S. Older adults with type 2 diabetes receiving metformin monotherapy received add-on therapy with either rosiglitazone, a thiazolidinedione insulin sensitizer, or glyburide. Cognitive function was assessed at baseline and week 24 using the Digit Symbol Substitution Test, the Rey Auditory Verbal Learning Test, and the Cambridge Neuropsychological Test Automated Battery.
RESULTS—Pretreatment fasting plasma glucose (FPG) in both groups was similar, and after 24 weeks both treatment groups showed similar significant reductions in FPG (2.1–2.3 mmol/l). Working memory improved with both rosiglitazone (P < 0.001) and glyburide (P = 0.017). Improvement (25–31% reduction in errors) was most evident on the Paired Associates Learning Test and was significantly correlated (r = 0.30) with improved glycemic control as measured by FPG.
CONCLUSIONS—Similar and statistically significant cognitive improvement was observed with both rosiglitazone and glyburide therapy, and the magnitude of this effect was correlated with the degree to which FPG improved. These results suggest that a cognitive benefit is achievable with pharmacological interventions targeting glycemic control.
Abbreviations: CANTAB, Cambridge Neuropsychological Test Automated Battery • FPG, fasting plasma glucose • HOMA, homeostasis model assessment • PAL, Paired Associates Learning
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Find additional patient-related information at:
This article has been cited by other articles:
|
|
 |
|
  N. Coley, S. Andrieu, V. Gardette, S. Gillette-Guyonnet, C. Sanz, B. Vellas, and A. Grand Dementia Prevention: Methodological Explanations for Inconsistent Results Epidemiol. Rev., September 8, 2008; (2008) mxn010v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dickinson and P. D. Harvey Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem Schizophr Bull, August 9, 2008; (2008) sbn097v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Umegaki, T. Kawamura, N. Mogi, T. Umemura, A. Kanai, and T. Sano Glucose control levels, ischaemic brain lesions, and hyperinsulinaemia were associated with cognitive dysfunction in diabetic elderly Age Ageing, July 1, 2008; 37(4): 458 - 461. [Full Text] [PDF]
|
|
|
|
 |
|
 M. W J Strachan, J. F Price, and B. M Frier Diabetes, cognitive impairment, and dementia BMJ, January 5, 2008; 336(7634): 6 - 6. [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Bowler and P. B. Gorelick Advances in Vascular Cognitive Impairment 2006 Stroke, February 1, 2007; 38(2): 241 - 244. [Full Text] [PDF]
|
|
|
|
 |
|
 Endocrinology & Metabolism News, April 2006 J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 17a - 17a. [Full Text] [PDF]
|
|
|
|
 |
|
 Better Mental Functioning Through Glycemic Control DOC News, April 1, 2006; 3(4): 12 - 12. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |